Liver function tests in children and adolescents receiving risperidone treatment for a year: A longitudinal, observational study from Turkey

Basit Öğe Kaydı
dc.authorid0000-0001-5207-6240en_US
dc.authorid0000-0002-3613-0523en_US
dc.contributor.authorKaraman, Mehmet Goksin
dc.contributor.authorErdoGan, Ayten
dc.contributor.authorTufan, Evren
dc.contributor.authorYurteri, Nihal
dc.contributor.authorOzdemir, Esra
dc.contributor.authorAnkarali, Handan
dc.date.accessioned2024-07-12T21:49:54Z
dc.date.available2024-07-12T21:49:54Z
dc.date.issued2011en_US
dc.departmentMaltepe Üniversitesien_US
dc.description.abstractObjective. To determine the changes in liver function tests after long-term risperidone treatment in a child and adolescent population. Methods. Weight, alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transpeptidase, alkaline phosphatase and serum bilirubin of the patients were assessed in pre-treatment period, and at the sixth and 12th months of treatment. One hundred children and adolescents (aged between 3 and 18 years) were enrolled to the study. Results. Liver enzyme and bilirubin levels are higher than normal in 21.0% of the patients without clinical symptoms. No cases of hepatic failure or jaundice were seen. Only in an 8-year-old boy were there ALT level increases up to three-fold and AST level increases up to two-fold. After discontinuation of the risperidone treatment, enzyme levels were normalized in this patient. Alkaline phosphatase, alanine and aspartate aminotransferases were the most frequently increased enzymes. Conclusion. In this study, after long-term risperidone treatment of children and adolescents there was no evidence of clinically significant increases of liver enzymes and bilirubin levels. These results indicate that risperidone treatment may rarely cause serious liver enzyme increases, and may commonly cause clinically insignificant changes in liver function tests.en_US
dc.identifier.doi10.3109/13651501.2011.582537
dc.identifier.endpage208en_US
dc.identifier.issn1365-1501
dc.identifier.issue3en_US
dc.identifier.pmid22121930en_US
dc.identifier.scopus2-s2.0-84860391792en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage204en_US
dc.identifier.urihttps://dx.doi.org/10.3109/13651501.2011.582537
dc.identifier.urihttps://hdl.handle.net/20.500.12415/8105
dc.identifier.volume15en_US
dc.identifier.wosWOS:000293921600006en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherINFORMA HEALTHCAREen_US
dc.relation.ispartofINTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICEen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmzKY01305
dc.subjectRisperidoneen_US
dc.subjectantipsychoticsen_US
dc.subjectALPen_US
dc.subjectASTen_US
dc.subjectALTen_US
dc.subjectliver function testsen_US
dc.subjectchildrenen_US
dc.subjectadolescentsen_US
dc.titleLiver function tests in children and adolescents receiving risperidone treatment for a year: A longitudinal, observational study from Turkeyen_US
dc.typeArticle
dspace.entity.typePublication

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu